BACKGROUND: The prognosis of children with diffuse intrinsic pontine gliomas (DIPG) is dismal. This study aims to evaluate the characteristics and treatment outcome of children with DIPG in a single center. METHODS: We reviewed the outcome of children with DIPG treated at the Oncology Institute of Istanbul University from February 1999 to May 2012. RESULTS: Fifty children (26 female, 24 male) with the median age of 7 years were analyzed. The median duration of symptoms was 30 days. All patients received radiotherapy (RT). Before the year 2000, 12 patients received only RT. Thirty-eight had concomitant and/or adjuvant chemotherapy with RT. Between 2000 and 2004, 17 patients received cis-platinum or vincristine as sensitizers during RT and CCNU + vincristine combination after RT. Since 2004, 21 patients received temozolomide (TMZ) concomitantly during RT and as adjuvant chemotherapy after RT. The median survival time of all patients was 13 months (1-160 months). Patients receiving RT + TMZ had a significantly higher overall survival than patients with only RT (p = 0.018). Patients receiving RT + chemotherapy other than TMZ also had a significantly higher overall survival than patients receiving only RT (p = 0.013). Patients receiving RT + TMZ + and chemotherapy other than TMZ had a significantly higher survival than patients receiving only RT (p = 0.005). CONCLUSION: In our series, patients receiving RT + TMZ and also patients receiving RT + chemotherapy other than TMZ had a significantly higher overall survival than patients treated with only RT. Hence, administering chemotherapy during and after RT seems to prolong survival in some DIPG patients.
BACKGROUND: The prognosis of children with diffuse intrinsic pontine gliomas (DIPG) is dismal. This study aims to evaluate the characteristics and treatment outcome of children with DIPG in a single center. METHODS: We reviewed the outcome of children with DIPG treated at the Oncology Institute of Istanbul University from February 1999 to May 2012. RESULTS: Fifty children (26 female, 24 male) with the median age of 7 years were analyzed. The median duration of symptoms was 30 days. All patients received radiotherapy (RT). Before the year 2000, 12 patients received only RT. Thirty-eight had concomitant and/or adjuvant chemotherapy with RT. Between 2000 and 2004, 17 patients received cis-platinum or vincristine as sensitizers during RT and CCNU + vincristine combination after RT. Since 2004, 21 patients received temozolomide (TMZ) concomitantly during RT and as adjuvant chemotherapy after RT. The median survival time of all patients was 13 months (1-160 months). Patients receiving RT + TMZ had a significantly higher overall survival than patients with only RT (p = 0.018). Patients receiving RT + chemotherapy other than TMZ also had a significantly higher overall survival than patients receiving only RT (p = 0.013). Patients receiving RT + TMZ + and chemotherapy other than TMZ had a significantly higher survival than patients receiving only RT (p = 0.005). CONCLUSION: In our series, patients receiving RT + TMZ and also patients receiving RT + chemotherapy other than TMZ had a significantly higher overall survival than patients treated with only RT. Hence, administering chemotherapy during and after RT seems to prolong survival in some DIPGpatients.
Authors: L S Lashford; P Thiesse; A Jouvet; T Jaspan; D Couanet; P D Griffiths; F Doz; J Ironside; K Robson; R Hobson; M Dugan; A D J Pearson; G Vassal; D Frappaz Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: Kenneth J Cohen; Richard L Heideman; Tianni Zhou; Emiko J Holmes; Robert S Lavey; Eric Bouffet; Ian F Pollack Journal: Neuro Oncol Date: 2011-02-22 Impact factor: 12.300
Authors: P G Fisher; S N Breiter; B S Carson; M D Wharam; J A Williams; J D Weingart; D R Foer; P T Goldthwaite; T Tihan; P C Burger Journal: Cancer Date: 2000-10-01 Impact factor: 6.860
Authors: James R Perry; Karl Bélanger; Warren P Mason; Dorcas Fulton; Petr Kavan; Jacob Easaw; Claude Shields; Sarah Kirby; David R Macdonald; David D Eisenstat; Brian Thiessen; Peter Forsyth; Jean-François Pouliot Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: J S Guillamo; A Monjour; L Taillandier; B Devaux; P Varlet; C Haie-Meder; G L Defer; P Maison; J J Mazeron; P Cornu; J Y Delattre Journal: Brain Date: 2001-12 Impact factor: 13.501
Authors: B L Maria; K Rehder; T A Eskin; L M Hamed; E B Fennell; R G Quisling; J P Mickle; R B Marcus; W E Drane; N P Mendenhall Journal: J Child Neurol Date: 1993-04 Impact factor: 1.987
Authors: Setty M Magaña; Timothy E Peterson; Jared E Evans; Paul A Decker; Vernadette Simon; Jeanette E Eckel-Passow; David J Daniels; Ian F Parney Journal: J Neurooncol Date: 2022-01-05 Impact factor: 4.130
Authors: Stefano Gabriele Vallero; Daniele Bertin; Maria Eleonora Basso; Laura Stefania Pittana; Anna Mussano; Franca Fagioli Journal: Childs Nerv Syst Date: 2014-01-14 Impact factor: 1.475
Authors: Matthew Gallitto; Stanislav Lazarev; Isaac Wasserman; James M Stafford; Suzanne L Wolden; Stephanie A Terezakis; Ranjit S Bindra; Richard L Bakst Journal: Adv Radiat Oncol Date: 2019-03-30
Authors: Muhammad A Parenrengi; Wihasto Suryaningtyas; Asra Al Fauzi; Abdul Hafid Bajamal; Kurnia Kusumastuti; Budi Utomo; Ahmad Muslim Hidayat Thamrin; Bagus Sulistiono Journal: Cancer Control Date: 2022 Jan-Dec Impact factor: 3.302